Both medications constitute a novel class of immunoglobulin treatments designed to block the coronavirus pathogen . Originally , sotrovimab, developed by Vir Biotechnology , demonstrated significant https://monicaiajx231339.blog-gold.com/59205133/sotrovimab-vir-7831-a-deep-analysis-into-the-immunoglobulin-therapy